IL15 and neoplasm: In agreement with our findings, a study in preclinical mouse models has shown that induction of type I IFNs through STING activation, results in tumor rejection by enhancing NK cell activation and cytotoxicity either directly or by upregulating IL-15 and IL-15Rα receptors (46).